On Friday, Arcus Biosciences Inc (NYSE: RCUS) was -14.36% drop from the session before settling in for the closing price of $25.14. A 52-week range for RCUS has been $6.50 – $26.40.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -10.20%. When this article was written, the company’s average yearly earnings per share was at -14.38%. With a float of $81.21 million, this company’s outstanding shares have now reached $107.10 million.
Arcus Biosciences Inc (RCUS) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Arcus Biosciences Inc stocks. The insider ownership of Arcus Biosciences Inc is 39.46%, while institutional ownership is 53.16%. The most recent insider transaction that took place on Dec 04 ’25, was worth 2,050,599. In this transaction President of this company sold 82,997 shares at a rate of $24.71, taking the stock ownership to the 954,063 shares. Before that another transaction happened on Dec 04 ’25, when Company’s Officer proposed sale 82,997 for $25.26, making the entire transaction worth $2,096,504.
Arcus Biosciences Inc (RCUS) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 12/31/2024, it has been observed that the corporation posted -1.03 earnings per share (EPS) during the time that was better than consensus figure (set at -1.2) by 0.17. Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -14.38% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.18% during the next five years compared to -10.20% drop over the previous five years of trading.
Arcus Biosciences Inc (NYSE: RCUS) Trading Performance Indicators
You can see what Arcus Biosciences Inc (RCUS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.65. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.10.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.43, a number that is poised to hit -1.13 in the next quarter and is forecasted to reach -3.99 in one year’s time.
Technical Analysis of Arcus Biosciences Inc (RCUS)
Compared to the last year’s volume of 1.18 million, its volume of 2.76 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 36.95%.
During the past 100 days, Arcus Biosciences Inc’s (RCUS) raw stochastic average was set at 72.27%, which indicates a significant increase from 19.50% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.50 in the past 14 days, which was higher than the 0.92 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.12, while its 200-day Moving Average is $12.16. Nevertheless, the first resistance level for the watch stands at $23.57 in the near term. At $25.61, the stock is likely to face the second major resistance level. The third major resistance level sits at $27.22. If the price goes on to break the first support level at $19.92, it is likely to go to the next support level at $18.31. Should the price break the second support level, the third support level stands at $16.27.
Arcus Biosciences Inc (NYSE: RCUS) Key Stats
There are 107,974K outstanding shares of the company, which has a market capitalization of 2.66 billion. As of now, sales total 258,000 K while income totals -283,000 K. Its latest quarter income was 26,000 K while its last quarter net income were -135,000 K.
